FIELD: medicine.
SUBSTANCE: invention can find application for the purpose of prediction of recurrence-free survival in cervical cancer (CC). The method involves patient's catalase activity and malondialdehyde in peripheral blood erythrocytes at the initial CC. If erythrocyte catalase activity is within 2.2 to 9.5 mmole/min/l, and if malondialdehyde is within 215.8 to 397.1 mcmole/l, the probability of 18-month recurrence-free survival makes 60%, and erythrocyte catalase activity within 10.5 to 19.4 mmole/min/l, the probability of 18-month recurrence-free survival makes 86%.
EFFECT: use of the presented invention provides the prediction of the recurrence-free survival period in local cervical cancer.
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR PREDICTION OF RECURRENCE-FREE SIRVIVAL IN CERVICAL CANCER BY BLOOD PLASMA CATALASE ACTIVITY TEST | 2012 |
|
RU2483308C1 |
| METHOD FOR PREDICTION OF RECURRENCE-FREE SIRVIVAL IN CERVICAL CANCER BY CANCER TISSUE GLUTATHIONE REDUCTASE ACTIVITY TEST | 2012 |
|
RU2483304C1 |
| METHOD FOR REDUCING STIFFNESS OF RED BLOOD CELL MEMBRANE IN PATIENTS SUFFERING FROM CERVICAL CANCER | 2013 |
|
RU2523345C1 |
| METHOD FOR PREDICTING THE PROGRESSION OF CERVICAL CANCER IN PATIENTS WITH STAGE IIB | 2022 |
|
RU2789500C1 |
| CERVICAL CANCER STAGING METHOD | 2016 |
|
RU2645111C2 |
| METHOD FOR DIAGNOSIS OF METASTASES TO LYMPH NODES OF SMALL PELVIS IN PATIENTS WITH RESECTABLE CERVICAL CANCER | 2020 |
|
RU2750769C2 |
| METHOD FOR PREVENTION OF HAEMATOGENOUS METASTASIS IN SURGICAL TREATMENT OF PATIENTS WITH LOCALLY ADVANCED CERVICAL CANCER | 2015 |
|
RU2591612C1 |
| METHOD FOR PREDICTION OF CERVICAL CANCER METASTASES | 2010 |
|
RU2436102C1 |
| METHOD OF PREDICTION OF PROBABILITY OF CERVICAL CANCER DETECTION BASED ON ROUTINE BLOOD PARAMETERS | 2023 |
|
RU2802395C2 |
| METHOD OF NEOADJUVANT TREATMENT OF PATIENTS WITH LOCALLY ADVANCED CERVICAL CANCER | 2017 |
|
RU2648642C1 |
